A Study to Learn About mRNA Vaccines Against Influenza in Adults

Part of paid clinical trials in Mobile, Alabama.

Sponsor
Pfizer
Study ID
NCT07431853
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Adults

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Vaccine Candidate #1 — BIOLOGICAL
    Investigational influenza Vaccine
  • Vaccine Candidate #2 — BIOLOGICAL
    Investigational influenza Vaccine
  • Vaccine Candidate #3 — BIOLOGICAL
    Investigational Influenza Vaccine
  • Vaccine Candidate #4 — BIOLOGICAL
    Investigational Influenza Vaccine
  • Vaccine Candidate #5 — BIOLOGICAL
    Investigational Influenza Vaccine
  • Vaccine Candidate #6 — BIOLOGICAL
    Investigational Influenza Vaccine
  • TIV1 or TIV2 — BIOLOGICAL
    Licensed influenza vaccine

Study Details

The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza virus). This study is seeking healthy participants 18 years of age or older. All participants in this study will receive only 1 dose in their arm, to deliver one of the experimental flu vaccines or one of the approved flu vaccines used for comparison. Participants will take part in this study for about 6 months, and participants will need to visit the study site at least 3 times. A blood sample will be taken at each of the 3 planned study visits and a swab from inside the nose will be taken at the first study visit.

Key Dates

Start date
Feb 23, 2026
Status verified
May 2026
Primary completion
Jun 22, 2027
Completion
Jun 22, 2027

Study Design

Enrollment
770 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: A
    mRNA influenza vaccine candidate #1 as a single intramuscular (IM) injection on Day 1.
  • Experimental: B
    mRNA influenza vaccine candidate #2 as a single IM injection on Day 1.
  • Experimental: C
    mRNA influenza vaccine candidate #3 as a single IM injection on Day 1.
  • Experimental: D
    mRNA influenza vaccine candidate #4 as a single IM injection on Day 1.
  • Experimental: E
    mRNA influenza vaccine candidate #5 as a single IM injection on Day 1.
  • Experimental: F
    mRNA influenza vaccine candidate #6 as a single IM injection on Day 1.
  • Active Comparator: G
    Licensed influenza vaccine (TIV1 or TIV2) as a single IM injection.

Primary Outcome Measure

Percentage of participants reporting prespecified local reactions following vaccination [ Time Frame: Within 7 days after vaccination ]

Central Contacts

Locations (15)

FacilityCityStateZIPSite coordinators
AMR ClinicalMobileAlabama36608-
Diablo Clinical Research, LLC d/b/a Flourish ResearchWalnut CreekCalifornia94598-
Clinical Research Consulting, LLCMilfordConnecticut06460-
George Washington Medical Faculty AssociatesWashington D.C.District of Columbia20037-
Indago Research & Health Center, IncHialeahFlorida33012-
Palm Springs Community Health CenterMiami LakesFlorida33014-
Clinical Research AtlantaStockbridgeGeorgia30281-
East-West Medical Research InstituteHonoluluHawaii96814-
AMR ClinicalKansas CityMissouri64114-
Rochester Clinical Research, LLCRochesterNew York14609-
DM Clinical Research - PhiladelphiaPhiladelphiaPennsylvania19107-
SMS Clinical Research LLCMesquiteTexas75149-
DM Clinical ResearchTomballTexas77375-
J. Lewis Research, Inc. / Foothill Family ClinicSalt Lake CityUtah84109-
Charlottesville Medical Research Center, LLCCharlottesvilleVirginia22911-

Find similar trials in Mobile, AL

By research site
AMR Clinical· Mobile, ALDiablo Clinical Research, LLC d/b/a Flourish Research· Walnut Creek, CAClinical Research Consulting, LLC· Milford, CTGeorge Washington Medical Faculty Associates· Washington D.C., DCIndago Research & Health Center, Inc· Hialeah, FLPalm Springs Community Health Center· Miami Lakes, FL

Related Studies